Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 63 от 222

Recruiting Phase 2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Pulmonary Hypertension

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Начало: 10.11.2025 Край: 18.07.2028 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +11 Pfizer NCT07073820

Recruiting Early Phase 1

Exploratory Study of UX-GIP001 Cell Therapy in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Epilepsy MTLE

This is an exploratory clinical trial (Protocol: UX-GIP001-101) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001. This is an open-label, single-arm study. All enrolled participants will receive the active investigational cell therapy. Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.

Начало: 10.11.2025 Край: 30.11.2028 Възраст: 18–75 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT07244328

Recruiting Phase 2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Ulcerative Colitis

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.

Начало: 10.11.2025 Край: 01.03.2029 Възраст: 18–80 г.

Austria, Brazil, Canada +14 Eli Lilly and Company NCT07186101

Recruiting Phase 3

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

ANCA Associated Vasculitis (AAV)

The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab

Начало: 10.11.2025 Край: 29.02.2028 Възраст: 18–75 г.

China Staidson (Beijing) Biopharmaceuticals Co., Ltd NCT07168161

Recruiting

Germline Testing for Predisposition to Myeloid Malignancies

Myeloid Malignancy Genetic Predisposition to Disease Myeloid Hematological Malignancies

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Начало: 10.11.2025 Край: 01.04.2033 Възраст: от 18 г.

United States Christopher Reilly NCT07112287

Recruiting

Use of Artificial Intelligence to Assess Trainee Communication Compared to Human Assessment

Communication Skills

This study will evaluate whether a web-based artificial intelligence platform (AI) (Clinical Mind AI \[CMAI\] Stanford, CA), can assess communication skills in anesthesiology trainees, including residents and fellows, in the setting of disclosing medical errors. All participants will participate in an AI-generated simulation by using the platform remotely, and CMAI will assess trainee performance immediately after the simulation.

Начало: 10.11.2025 Край: 14.11.2026 Възраст: 18–99 г.

United States Stanford University NCT07107880

Recruiting

Efficacy of Narrative Therapy for Older People With Depression

Depression

The research aims to investigate the efficacy of a narrative therapy group in reducing depressive symptoms among older people. This study adopts a mixed methods research design, involving both quantitative and qualitative approaches. In the quantitative study, a randomised controlled trial will compare a narrative therapy group with a waitlist control group to determine whether an eight-session narrative therapy group can reduce depressive symptoms in older people. The eight-session narrative therapy group will be delivered by a trained and experienced social worker or counsellor, and intervention outcomes will be assessed before and after the intervention using a standardised assessment tool for depressive symptoms. The qualitative study aims to examine the benefits, advantages, and limitations of the narrative therapy group from the users' perspective.

Начало: 10.11.2025 Край: 31.08.2026 Възраст: от 60 г.

Hong Kong City University of Hong Kong NCT07371988

Recruiting

Impact of Indoor Overheating on Physiological Strain in Children

Heat Stress Physiological Stress Cognitive Change

Communities worldwide are experiencing increasing heat extremes that challenge the limits of human thermoregulation, particularly among vulnerable populations such as children. Compared with adults, children are more susceptible to heat related illness due to less efficient thermoregulatory systems and difficulty recognizing early signs of heat stress. In addition, prolonged heat exposure can adversely affect their mental health, contributing to cognitive decline, heightened anxiety, and irritability. As children spend substantial time in hot environments at school and at home, and as these conditions intensify with climate change, actions to safeguard their health are essential. Yet our understanding of heat exposure effects in children remains incomplete, hindering the development of evidence based strategies to protect them. To address this gap, the investigators aim to evaluate whether an indoor temperature limit of 26 °C (45 percent relative humidity), the upper threshold recommended to protect older adults, can effectively prevent dangerous increases in physiological strain and declines in cognitive function in children during a simulated daylong heatwave. The preliminary study will assess physiological and cognitive responses in children aged 10 to 15 years during a 6 hour exposure (approximating a typical school day) to two conditions: (1) the recommended indoor temperature upper limit (26 °C) and (2) a high heat condition representative of homes and schools without air conditioning during extreme heat events (36 °C). In both conditions, children will remain seated at rest while wearing light clothing (t shirt and shorts), with the exception of performing 15 minutes of stepping exercise (6-6.5 METS) each hour (excluding the lunch period) to reflect typical daily activity in a school setting. This experimental design will allow investigators to determine whether maintaining indoor temperatures at the recommended upper limit for older adults sufficiently mitigates physiological strain in children.

Начало: 08.11.2025 Край: 31.12.2026 Възраст: 10–15 г.

Canada University of Ottawa NCT07261202

Recruiting

Heat Stress in Individuals With Schizophrenia

Heat Stress Physiological Stress Cognitive Change

Schizophrenia is a severe mental illness affecting approximately 24 million people worldwide and is associated with more than double the all cause mortality risk of the general population. Emerging evidence demonstrates that elevated temperatures acutely worsen mental health symptoms and significantly increase the risk of heat related morbidity and mortality. For people living with schizophrenia, prolonged exposure to heat can exacerbate psychiatric symptoms, impair judgment and decision making, and reduce the ability to engage in protective behaviors such as increasing hydration, reducing clothing, improving ventilation, or seeking cooler environments. As a result, individuals with schizophrenia may experience higher rates of heat related illness. To date our understanding of heat exposure effects in individuals with schizophrenia remains incomplete, hindering the development of evidence-based strategies to protect them. Thus, the primary objective of this exploratory study is to gather preliminary data on the effects of indoor overheating on physiological responses (core body temperature and cardiovascular function), cognitive performance (attention, working memory, and reaction time), and mood in adults with schizophrenia. Specifically, we will assess whether maintaining indoor conditions at the upper recommended temperature limit for older adults (26°C, 45% relative humidity \[RH\]; PMID: 38329752) is sufficient to mitigate physiological strain compared with exposure to a hot indoor environment (36°C, 45% RH) representative of non-air-conditioned homes during extreme heat events in individuals with schizophrenia. In both conditions, the individual will remain seated at rest while wearing light clothing (t shirt and shorts), with the exception of performing 15 minutes of stepping exercise (4-4.5 METS) each hour (excluding the lunch period) to reflect typical daily activities of daily living.

Начало: 08.11.2025 Край: 01.07.2027 Възраст: 18–85 г.

Canada University of Ottawa NCT07383324

Recruiting Phase 4

45th Multicenter Airway Research Collaboration

Asthma Acute Asthma Exacerbation Asthma Asthma Control Level

The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).

Начало: 07.11.2025 Край: 01.06.2027 Възраст: 18–54 г.

United States Massachusetts General Hospital NCT07166939

Recruiting Phase 1/2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Prostate Cancers Breast Cancer Lung Cancers Ovarian Cancer +3

This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.

Начало: 07.11.2025 Край: 26.10.2027 Възраст: от 18 г. Treatment

Australia Filamon LTD NCT06926075

Recruiting Phase 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Non-muscle Invasive Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin. For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial participation for each participant will vary as long-term follow-up will continue after treatment discontinuation until loss to-follow-up or death, or until the study is stopped by the sponsor.

Начало: 06.11.2025 Край: 28.01.2033 Възраст: от 18 г.

France, Israel, South Korea +2 Pfizer NCT07206225

Recruiting Phase 2

Improving Vaccine Protection for Older Adults

Immune System Responses and Trained Immunity After AS01 Administration Healthy Adult

As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines. This was clearly seen during the COVID-19 pandemic, where older adults were more likely to develop severe illness. Researchers have made an interesting discovery about AS01, an ingredient already used in successful vaccines like the shingles vaccine. They found clues that AS01 might work like a general fitness trainer for the immune system, potentially making it stronger and better at fighting off various types of infections, not just specific ones. To confirm this possibility, we are conducting this research study with adults aged 21-59 to test whether AS01 by itself can boost and train the immune system, how long this boost lasts, and if it actually helps you fight off other infections more effectively.

Начало: 06.11.2025 Край: 28.02.2029 Възраст: 21–59 г.

Singapore Singapore General Hospital NCT07527247

Recruiting Phase 2

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study. The randomized treatment duration will be up to approximately 48 weeks.

Начало: 06.11.2025 Край: 27.04.2028 Възраст: от 18 г. Treatment

Australia, Canada, Chile +15 Sanofi NCT07170917

Recruiting Phase 2

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Bronchiectasis With Pseudomonas Aeruginosa Colonization

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Начало: 06.11.2025 Край: 14.06.2028 Възраст: от 12 г. Prevention

Argentina, Australia, Belgium +21 AstraZeneca NCT07088926

Recruiting

Influence of Dressings on Skin pH Alterations in Simulated Skin Folds in Healthy Subjects

Skin Folds

This study investigates the effect of different dressings on skin pH when applied to a simulated skin fold environment.

Начало: 05.11.2025 Край: 30.04.2026 Възраст: 18–80 г.

Sweden Essity Hygiene and Health AB NCT07547488

Recruiting

A Study to Evaluate the Performance of a Wireless Optical Sensor Capsule in Detection of UGIB

Melena Gastrointestinal Bleeding Hematemesis

Upper gastrointestinal bleeding (UGIB) is a common and potentially lethal medical emergency, which requires hospitalization and healthcare resources. Despite the changing epidemiology and advancement of endoscopic therapy in the recent decade, the all-cause mortality of UGIB remains high (\>2%). An accurate risk stratification is necessary to triage patients into low- or high-risk groups, in order to inform clinicians for the necessity and timing of urgent endoscopy. However, existing pre-endoscopy risk scores, such as the Glasgow-Blatchford score (GBS), Rockall score and AIMS65 score, are suboptimal in predicting relevant clinical outcomes. An alternative strategy for risk stratification is urgently warranted in patients with UGIB to guide the next step of management. In a pre-clinical study, the sensitivity and specificity of HemoPill® prototype were 95% and 87.5% respectively, when the sensors were positioned close to the bleeding point. Furthermore, several human clinical studies have proven the feasibility and accuracy of HemoPill® in healthy volunteers and patients with suspected UGIB. Capsule ingestion was well tolerated with no device-related adverse event or capsule retention. All patients with negative HI were found to have no active endoscopic bleeding (true negative, 100%, 17/17). In patients with bleeding \>20ml, true positive HI signals were detected (100%, 2/2) In a retrospective multi-center study, 61 patients with suspected UGIB were recruited to use HemoPill®. Among the capsule-positive cases, subsequent endoscopy confirmed active bleeding in 57% (20/35) of them. None of the capsule-negative patients rebled (0%, 0/25), which prevented unnecessary emergent endoscopy in 72% of them (18/25).

Начало: 05.11.2025 Край: 30.04.2028 Възраст: от 18 г.

Hong Kong Chinese University of Hong Kong NCT06715293

Recruiting Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Locally Advanced Cervical Adenocarcinoma Locally Advanced Cervical Adenosquamous Carcinoma Locally Advanced Cervical Squamous Cell Carcinoma Stage IIIA Cervical Cancer FIGO 2018 +4

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.

Начало: 05.11.2025 Край: 31.12.2030 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT07061977

Recruiting Phase 2

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Colorectal Cancer Liver Metastases (CRLM)

This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.

Начало: 04.11.2025 Край: 01.11.2028 Възраст: от 18 г.

China Fudan University NCT07544784

Recruiting

Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

Aortic Arch Aneurysm Aortic Arch Dissection Chronic Aortic Dissection Acute Aortic Dissection

The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.

Начало: 04.11.2025 Край: 01.07.2032 Възраст: 18–80 г.

United States Artivion Inc. NCT07089576

1 … 61 62 63 64 65 … 222